Secondary analysis of 895 patients from childhood cancer trials (most randomised to dexrazoxane) given doxorubicin: dexrazoxane was associated with better LV systolic function (z-score difference 0.4) and lower hazard of reduced LV function after 1 (0.58) and 5 years (0.54).
Secondary analysisn = 895
Mobley et al. Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2